Q2 2025 Guardant Health Inc Earnings Call Transcript
Key Points
- Guardant Health Inc (GH) reported a 31% year-over-year revenue growth to $232 million, driven by strong performance across oncology, biopharma, and screening business lines.
- The company's oncology business saw a 22% revenue increase to $159 million, with oncology volumes increasing 30% year-over-year.
- Guardant360 Liquid experienced over 20% year-over-year growth for the fourth consecutive quarter, showcasing strong market demand.
- The Shield CRC screening test generated $15 million in revenue with high adherence rates over 90%, indicating strong market acceptance.
- Guardant Health Inc (GH) raised its full-year 2025 revenue guidance to $915 million to $925 million, reflecting confidence in continued growth.
- Despite strong revenue growth, Guardant Health Inc (GH) reported an adjusted EBITDA loss of $51.9 million for Q2 2025.
- The company continues to face challenges in achieving profitability, with a focus on reinvesting gross profits into sales and marketing.
- There is uncertainty regarding the timing of Shield V2 data release, which could impact future product launches.
- The potential replacement of the USPSTF panel poses a risk to the inclusion of Shield in national screening guidelines.
- Guardant Health Inc (GH) anticipates a potential decrease in Shield ASP in the second half of 2025 due to changes in the payer mix.
Good afternoon, and thank you for attending the Guardant Health Q2 2025 earnings conference call. My name is Jason, and I'll be the moderator today. (Operator Instructions)
I would now like to pass the conference over to your host, Zarak Khurshid.
Thank you. Earlier today, Guardant Health released financial results for the quarter ended June 30, 2025. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO; AmirAli Talasaz, Co-CEO; and Mike Bell, Chief Financial Officer.
Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items.
Additional information regarding material risks and uncertainties
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
